Zoetis Inc. (NYSE:ZTS) saw unusually large options trading activity on Wednesday. Stock traders bought 25,516 call options on the company. This represents an increase of approximately Infinity compared to the average volume of 0 call options.

A number of hedge funds have recently made changes to their positions in ZTS. Janus Henderson Group PLC raised its position in Zoetis by 7,717.4% in the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock worth $362,372,000 after acquiring an additional 5,734,776 shares during the period. Alliancebernstein L.P. raised its position in Zoetis by 55.4% in the second quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock worth $646,905,000 after acquiring an additional 3,695,449 shares during the period. Waddell & Reed Financial Inc. raised its position in Zoetis by 65.9% in the first quarter. Waddell & Reed Financial Inc. now owns 5,434,371 shares of the company’s stock worth $290,033,000 after acquiring an additional 2,157,803 shares during the period. BlackRock Inc. raised its position in Zoetis by 3.9% in the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock worth $2,338,957,000 after acquiring an additional 1,412,829 shares during the period. Finally, AJO LP raised its position in Zoetis by 4,506.8% in the second quarter. AJO LP now owns 1,271,425 shares of the company’s stock worth $79,311,000 after acquiring an additional 1,243,826 shares during the period. 93.04% of the stock is currently owned by institutional investors and hedge funds.

Zoetis (NYSE ZTS) opened at $68.69 on Friday. The company has a debt-to-equity ratio of 2.13, a quick ratio of 1.17 and a current ratio of 2.01. The firm has a market cap of $32,799.38, a price-to-earnings ratio of 30.88, a price-to-earnings-growth ratio of 2.01 and a beta of 1.02.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. Zoetis had a net margin of 18.29% and a return on equity of 66.15%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same period last year, the firm earned $0.52 earnings per share. The firm’s revenue was up 8.5% on a year-over-year basis. analysts anticipate that Zoetis will post 2.36 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be given a $0.105 dividend. This represents a $0.42 annualized dividend and a yield of 0.61%. The ex-dividend date of this dividend is Wednesday, November 8th. Zoetis’s dividend payout ratio is 22.11%.

A number of equities research analysts have commented on ZTS shares. Cowen and Company set a $60.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Tuesday, July 11th. Deutsche Bank AG reaffirmed a “buy” rating and set a $65.00 price objective (up from $62.00) on shares of Zoetis in a report on Monday, July 17th. Stifel Nicolaus reaffirmed a “buy” rating and set a $65.00 price objective on shares of Zoetis in a report on Friday, July 21st. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $62.00 price objective on shares of Zoetis in a report on Monday, August 7th. Finally, Cantor Fitzgerald set a $75.00 price objective on shares of Zoetis and gave the company a “buy” rating in a report on Monday, August 14th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $67.06.

TRADEMARK VIOLATION WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.watchlistnews.com/traders-purchase-large-volume-of-call-options-on-zoetis-zts/1677092.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.